Barclays trims AstraZeneca and GSK targets on U.K. stock notes
In analyst action on U.K. stocks, Barclays cut AstraZeneca’s price target to 16000 pence from 16500, keeping an Overweight stance. Barclays also cut GSK’s target, with more details truncated in the feed.
K. 00 am- BARCLAYS CUTS ASTRAZENECA PRICE TARGET TO 16000 (16500) PENCE - 'OVERWEIGHT'- BARCLAYS CUTS GSK PRI…